← All trials
NCT06707181
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2023
- Primary completion
- May 20, 2024
- Completion date
- Aug 18, 2024
- First posted
- Nov 27, 2024
- Last posted
- Nov 27, 2024
- Enrollment
- 180
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beni Suef UniversityLead sponsor
- Beni Suef UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.